|
|
Browse products Anticancer agents in preclinical trials Anticancer molecular libraries Other drug agents
|
MedKoo product information:
CEP-28122
Description of CEP-28122: CEP-28122 is a Highly Potent and Selective Orally Active Inhibitor of Anaplastic Lymphoma Kinase with Antitumor Activity in Experimental Models of Human Cancers. (source: Mol Cancer Ther; 11(3); 670-9.)
Current developer: Cephalon (now part of Teva Pharm).
In vitro activity of CEP-28122: the follow data was reported by Cheng M et al.
(data reported in Mol Cancer Ther. 2012 Mar;11(3):670-9.)
1: Cheng M, Quail MR, Gingrich DE, Ott GR, Lu L, Wan W, Albom MS, Angeles TS, Aimone LD, Cristofani F, Machiorlatti R, Abele C, Ator MA, Dorsey BD, Inghirami G, Ruggeri BA. CEP-28122, a Highly Potent and Selective Orally Active Inhibitor of Anaplastic Lymphoma Kinase with Antitumor Activity in Experimental Models of Human Cancers. Mol Cancer Ther. 2012 Mar;11(3):670-9. Epub 2011 Dec 27. PubMed PMID: 22203728. |
Contact MedKoo: Email: sales@medkoo.com
(Keyword; CAS#; MedKoo code#)
|
||||||||||||||
About us | Services | Products | News | Careers | Contact us